Share This

Related Topics News - Drugs

     
 Title only   |   Print    Next page > 
     
中國生物製藥TDI01混懸液新適應症被納入突破性治療藥物程序

2025-06-16T  
《大行》野村升石藥集團目標價至10.22元 評級「買入」

2025-06-16T  
石藥與阿斯利康訂立戰略研發合作協議

2025-06-13T  
《大行》里昂升中生製藥目標價至7元 維持「跑贏大市」

2025-06-13T  
中生製藥擬未來三年每年上市5款創新產品 料近期落地對外授權交易

2025-06-13T  
中生製藥彈逾13% 即將有重磅對外授權落地

2025-06-12T  
港股通騰訊淨流出18.92億港元

2025-06-10T  
中生製藥TQB2868注射液獲CDE批准開展III期註冊臨床研究

2025-06-10T  
石藥集團癌症藥物SYS6040獲批於美國開展臨床研究

2025-06-10T  
《大行》大摩列康龍化成為中型CRO/CDMO首選股 長期看好昭衍泰格

2025-06-10T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.